SuppReading3

SuppReading3 - REPORTS References and Notes Fig. 4....

Info iconThis preview shows pages 1–2. Sign up to view the full content.

View Full Document Right Arrow Icon
product is required for this regulated release. Similar to inactive ( 25 ), tyramine increas- es initial cocaine responsiveness in per o flies. Exposure of tyramine-fed per o flies to 35 m g of cocaine induced behaviors normally seen in control flies exposed to 75 m g (Fig. 4). Thus, although long-term increase of tyra- mine levels can affect initial cocaine respon- siveness, it is not sufficient for sensitization in flies lacking normal per function. A unifying feature of most genes that regulate circadian rhythmicity in Drosophila and vertebrates is the PAS dimerization do- main, common to a subset of basic helix- loop-helix transcription factors ( 26 , 27 ). Within the circadian cycle, CLOCK/CYCLE heterodimers activate per transcription, whereas PER/TIM heterodimers inhibit the activity of CLOCK/CYCLE ( 28 30 ). We find that mutations in per , clock , and cycle share the same cocaine phenotype: a deficien- cy in the ability to sensitize after one or more drug exposures. This similarity leads us to suspect that as in circadian behaviors, these genes are functioning in a common pathway. In contrast to the above mentioned genes, the tim o mutant showed normal cocaine re- sponses. The implication of this finding is two- fold. First, there must be an as yet unidentified PER binding partner that is specifically in- volved in regulation of drug responsiveness. Second, drug responsiveness is likely regulated by per expression in a set of cells distinct from those involved in circadian function. In tim o mutants, PER levels are constitutively low ( 19 , 20 ); if the same TIM-containing cells were involved in circadian and cocaine responses, tim o flies should not sensitize. References and Notes 1. C. McClung and J. Hirsh, Curr. Biol. 8 , 109 (1998). 2. A. C. Morse, V. G. Erwin, B. C. Jones, Physiol. Behav. 58 , 891 (1995). 3. B. K. Tolliver, J. K. Belknap, W. E. Woods, J. M. Carney, J. Pharmacol. Exp. Ther. 270 , 1230 (1994). 4. A. Goodman, and A. Gilman, in The Pharmalcological Basis of Therapeutics , A. Gilman, T. Rall, A. Nies, P. Taylor, Eds. (McGraw-Hill, New York, 1990), p. 417. 5. T. E. Robinson and K. C. Berridge, Brain Res. Brain Res. Rev. 18 , 247 (1993). 6. S. M. Strakowski, K. W. Sax, M. J. Setters, P. E. Keck Jr., Biol. Psychiatry 40 , 872 (1996). 7. R. Andretic and J. Hirsh, in preparation. 8. M. W. Young, Annu. Rev. Biochem. 67 , 135 (1998). 9. R. J. Konopka, and S. Benzer, Proc. Natl. Acad. Sci. U.S.A. 68 , 2112 (1971). 10. D. J. Henry and F. J. White, J. Neurosci. 15 , 6287 (1995). 11. E. J. Nestler and G. K. Aghajanian, Science 278 ,58 (1997). 12. F. J. White, X.-T. Hu, D. J. Henry, S.-F. Zhang, in The Neurobiology of Cocaine: Cellular and Molecular Mechanisms , R. P. Hammer, Ed. (CRC, Boca Raton, FL, 1995), p. 81.
Background image of page 1

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
Image of page 2
This is the end of the preview. Sign up to access the rest of the document.

Page1 / 4

SuppReading3 - REPORTS References and Notes Fig. 4....

This preview shows document pages 1 - 2. Sign up to view the full document.

View Full Document Right Arrow Icon
Ask a homework question - tutors are online